RPRX Earnings
Latest Revenue674.1M
Latest Net Income81.5M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.04 | 674.1M | 81.5M | +16.5% | -50.0% |
| Q1 2026 | $0.67 | 630.6M | 468.3M | +11.0% | +21.8% |
| Q4 2025 | $0.50 | 622.0M | 355.9M | +4.8% | +6.4% |
| Q3 2025 | $0.67 | 609.3M | 444.2M | +7.9% | -45.1% |
| Q2 2025 | $0.08 | 578.7M | 92.6M | +7.7% | -65.2% |
| Q1 2025 | $0.55 | 568.2M | 434.4M | +0.0% | +5,400.0% |
| Q4 2024 | $0.47 | 593.6M | 334.4M | -0.4% | -57.7% |
| Q3 2024 | $1.22 | 564.7M | 806.4M | +5.3% | +662.5% |
| Q2 2024 | $0.23 | 537.3M | 194.4M | — | — |
| Q1 2024 | $0.01 | 568.0M | -4273000 | — | — |
| Q4 2023 | $1.11 | 596.1M | 717.6M | — | — |
| Q3 2023 | $0.16 | 536.3M | 122.1M | — | — |
Royalty Pharma (RPRX) — Earnings